vs

Side-by-side financial comparison of Chicago Atlantic Real Estate Finance, Inc. (REFI) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Chicago Atlantic Real Estate Finance, Inc. is the larger business by last-quarter revenue ($14.2M vs $12.5M, roughly 1.1× Avidity Biosciences, Inc.). Chicago Atlantic Real Estate Finance, Inc. runs the higher net margin — 57.3% vs -1398.3%, a 1455.6% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 1.2%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 3.7%).

Chicago Atlantic Real Estate Finance, Inc. is a commercial real estate finance firm that primarily originates, underwrites, and manages secured senior mortgage loans for US commercial real estate assets. Its core segments include multifamily residential, industrial, retail, and office properties, serving experienced real estate operators and project sponsors.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

REFI vs RNA — Head-to-Head

Bigger by revenue
REFI
REFI
1.1× larger
REFI
$14.2M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+432.8% gap
RNA
434.0%
1.2%
REFI
Higher net margin
REFI
REFI
1455.6% more per $
REFI
57.3%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
3.7%
REFI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
REFI
REFI
RNA
RNA
Revenue
$14.2M
$12.5M
Net Profit
$8.2M
$-174.4M
Gross Margin
Operating Margin
57.3%
-1513.5%
Net Margin
57.3%
-1398.3%
Revenue YoY
1.2%
434.0%
Net Profit YoY
3.0%
-117.0%
EPS (diluted)
$0.38
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
REFI
REFI
RNA
RNA
Q4 25
$14.2M
Q3 25
$13.7M
$12.5M
Q2 25
$14.4M
$3.8M
Q1 25
$13.0M
$1.6M
Q4 24
$14.1M
$3.0M
Q3 24
$14.5M
$2.3M
Q2 24
$13.2M
$2.0M
Q1 24
$13.2M
$3.5M
Net Profit
REFI
REFI
RNA
RNA
Q4 25
$8.2M
Q3 25
$8.9M
$-174.4M
Q2 25
$8.9M
$-157.3M
Q1 25
$10.0M
$-115.8M
Q4 24
$7.9M
$-102.3M
Q3 24
$11.2M
$-80.4M
Q2 24
$9.2M
$-70.8M
Q1 24
$8.7M
$-68.9M
Operating Margin
REFI
REFI
RNA
RNA
Q4 25
57.3%
Q3 25
65.3%
-1513.5%
Q2 25
61.5%
-4448.7%
Q1 25
77.0%
-8360.9%
Q4 24
56.3%
-4069.6%
Q3 24
77.5%
-4200.9%
Q2 24
69.7%
-4040.4%
Q1 24
65.9%
-2178.6%
Net Margin
REFI
REFI
RNA
RNA
Q4 25
57.3%
Q3 25
65.3%
-1398.3%
Q2 25
61.5%
-4089.3%
Q1 25
77.0%
-7360.0%
Q4 24
56.3%
-3439.5%
Q3 24
77.5%
-3441.7%
Q2 24
69.7%
-3461.8%
Q1 24
65.9%
-1943.4%
EPS (diluted)
REFI
REFI
RNA
RNA
Q4 25
$0.38
Q3 25
$0.42
$-1.27
Q2 25
$0.41
$-1.21
Q1 25
$0.47
$-0.90
Q4 24
$0.39
$-0.80
Q3 24
$0.56
$-0.65
Q2 24
$0.46
$-0.65
Q1 24
$0.47
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
REFI
REFI
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$14.9M
$350.2M
Total DebtLower is stronger
$49.3M
Stockholders' EquityBook value
$307.8M
$1.9B
Total Assets
$424.9M
$2.1B
Debt / EquityLower = less leverage
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
REFI
REFI
RNA
RNA
Q4 25
$14.9M
Q3 25
$28.9M
$350.2M
Q2 25
$35.6M
$243.9M
Q1 25
$9.9M
$254.2M
Q4 24
$26.4M
$219.9M
Q3 24
$6.8M
$370.2M
Q2 24
$7.1M
$575.8M
Q1 24
$6.9M
$471.4M
Total Debt
REFI
REFI
RNA
RNA
Q4 25
$49.3M
Q3 25
$49.3M
Q2 25
$49.2M
Q1 25
$49.2M
Q4 24
$49.1M
Q3 24
$54.0M
Q2 24
$76.8M
Q1 24
Stockholders' Equity
REFI
REFI
RNA
RNA
Q4 25
$307.8M
Q3 25
$309.9M
$1.9B
Q2 25
$310.0M
$1.2B
Q1 25
$310.8M
$1.3B
Q4 24
$309.0M
$1.4B
Q3 24
$295.5M
$1.5B
Q2 24
$292.7M
$1.2B
Q1 24
$286.0M
$830.9M
Total Assets
REFI
REFI
RNA
RNA
Q4 25
$424.9M
Q3 25
$427.1M
$2.1B
Q2 25
$455.2M
$1.4B
Q1 25
$414.7M
$1.5B
Q4 24
$435.1M
$1.6B
Q3 24
$365.9M
$1.6B
Q2 24
$386.5M
$1.3B
Q1 24
$383.7M
$951.5M
Debt / Equity
REFI
REFI
RNA
RNA
Q4 25
0.16×
Q3 25
0.16×
Q2 25
0.16×
Q1 25
0.16×
Q4 24
0.16×
Q3 24
0.18×
Q2 24
0.26×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
REFI
REFI
RNA
RNA
Operating Cash FlowLast quarter
$28.8M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
3.53×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
REFI
REFI
RNA
RNA
Q4 25
$28.8M
Q3 25
$8.2M
$-156.2M
Q2 25
$6.5M
$-199.7M
Q1 25
$7.6M
$-124.8M
Q4 24
$23.2M
$-99.9M
Q3 24
$8.2M
$-65.6M
Q2 24
$6.2M
$-65.0M
Q1 24
$6.9M
$-70.4M
Free Cash Flow
REFI
REFI
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
REFI
REFI
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
REFI
REFI
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
REFI
REFI
RNA
RNA
Q4 25
3.53×
Q3 25
0.92×
Q2 25
0.73×
Q1 25
0.76×
Q4 24
2.92×
Q3 24
0.73×
Q2 24
0.68×
Q1 24
0.79×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons